NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study to Learn How Different Amounts of the Study Medicine Danuglipron Are Taken up Into the Blood in Otherwise Healthy Adults With Overweight or Obesity

NCT06568731

CompletedPhase 1

Sponsor: Pfizer

Conditions: Obesity

Interventions: Danuglipron

Countries: United States

The purpose of this study is to learn the following about the study medicine, danuglipron, after multiple days of dosing in healthy adults who are overweight or obese: * how the study medicine, danuglipron, is taken up into the blood * about the safety and tolerability of danuglipron The total number of weeks of the study is about 15 (about 4 months).

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: Yes

Study type: INTERVENTIONAL

Eligibility criteria

Key Inclusion Criteria:

* 18 years of age or older
* Body mass index (BMI) of ≥25.0-45.4 kg/m2; and a total body weight \>50 kg (110 lb)

Key Exclusion Criteria:

* Evidence or history of any clinically significant medical conditions or laboratory abnormality
* Any condition possibly affecting drug absorption
* Known intolerance/hypersensitivity to a GLP-1R agonist

Locations (1)

New Haven, Connecticut, United States